芴-9-甲胺盐酸盐 | 34221-61-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: 芴-9-甲胺盐酸盐
• 英文名称: 9-aminomethylfluorene hydrochloride
• 英文别名: 9H-Fluoren-9-ylmethylamine hydrochloride；fluoren-9-yl-methylamine hydrochloride；(9H-Fluoren-9-YL)methanamine hydrochloride；9H-fluoren-9-ylmethanamine;hydrochloride
• CAS: 34221-61-9
• 化学式: C₁₄H₁₃N*ClH
• 分子量: 231.725
• InChiKey: GISJMTUTYQLZHT-UHFFFAOYSA-N

物化性质

• 熔点：
  294 °C (decomp)

计算性质

• 辛醇/水分配系数(LogP)：
  3.18
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险标志：
  GHS07
• 危险性描述：
  H319
• 危险性防范说明：
  P305 + P351 + P338
• 海关编码：
  2921499090

反应信息

• 作为反应物：
  描述：

  芴-9-甲胺盐酸盐 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 作用下， 以 吡啶 、 甲醇 为溶剂， 反应 22.0h， 生成 9-亚甲基芴
  参考文献：
  名称：

  四组分缩合（4CC）合成中的碱不稳定胺组分

  摘要：

  对于模型肽合成，描述了在四组分缩合（4CC）合成中使用9-氨基甲基芴作为am组分。

  DOI：

  10.1039/c39810000491

文献信息

• Organic Compounds
  申请人：Fairhurst Robin Alec

  公开号：US20090099214A1

  公开（公告）日：2009-04-16

  A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein U, R 1 , R 2 and R 3 are as defined herein.

  一种化合物的分子式为（I），或其立体异构体或药学上可接受的盐，以及它们的制备和用作制药的方法，其中U、R1、R2和R3的定义如本文所述。
• Urea, thiourea and guanidine compounds and their use as anti-viral agents
  申请人：ELI LILLY AND COMPANY

  公开号：EP0806205A2

  公开（公告）日：1997-11-12

  The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.

  本发明提供了通过抑制病毒与宿主细胞融合来抑制包膜病毒的化合物。病毒可在受感染的细胞、易受感染的细胞或有需要的哺乳动物中受到抑制。
• New triazine derivatives as potent modulators of multidrug resistance
  作者：Alain Dhainaut、Gilbert Regnier、Ghanem Atassi、Alain Pierre、Stephane Leonce、Laurence Kraus-Berthier、Jean Francois Prost

  DOI：10.1021/jm00091a017

  日期：1992.6

  A series of 70 triazine derivatives have been synthesized and tested for their capacity to modulate multidrug resistance (MDR) in DC-3F/AD and KB-A1 tumor cells in vitro, in comparison with verapamil (VRP), a calcium channel antagonist currently used in therapy as an antihypertensive drug, which also shows MDR modulating activity. Among the 12 selected compounds, 16 (S9788) showed high MDR reversing properties in vitro (300- and 6-fold VRP at 5-mu-M in DC-3F/AD and KB-A1 cells, respectively) and induced a strong accumulation of adriamycin. The relationship between the increase of ADR accumulation and the fold reversal induced by these compounds and their lack of effects on the sensitive DC-3F cells suggest that they act mainly by inhibiting the P-glycoprotein (Pgp) catalyzed efflux of cytotoxic agents, as already described for a majority of MDR modulators. In vivo, in association with the antitumor drug vincristine (0.25 mg/kg), 16 (100 mg/kg) increased the TIC by 39% in mice bearing the resistant tumor cell line P388/VCR. According to these interesting properties, 16 was selected for a clinical development because it was more bioavailable than 34, even though it was less active.
• Exploiting the Dual Reactivity of <i>o</i>-Isocyanobenzamide:  Three-Component Synthesis of 4-Imino-4<i>H</i>-3,1-benzoxazines
  作者：Damien Bonne、Mouloud Dekhane、Jieping Zhu

  DOI：10.1021/ol052239w

  日期：2005.11.1

  A multicomponent synthesis of 4-imino-4H-3,1-benzoxazines is developed. Heating a toluene solution of an aldehyde (6), an amine (7), and an isonitrile (5) in the presence of a stoichiometric amount of ammonium chloride at 60 degrees C for 12 h produces the title compound in good to excellent yields.
• PURINE DERIVATIVES WITH ACTIVITY TO THE ADENOSINE A2A RECEPTOR
  申请人：Novartis AG

  公开号：EP2013210A1

  公开（公告）日：2009-01-14